US2022411762A1PendingUtilityA1

Method for producing pancreatic endocrine cells, and transdifferentiation agent

73
Assignee: JUNTENDO EDUCATIONAL FOUNDPriority: Oct 29, 2015Filed: Sep 2, 2022Published: Dec 29, 2022
Est. expiryOct 29, 2035(~9.3 yrs left)· nominal 20-yr term from priority
C12N 15/1068C07K 14/4702C12N 5/0676C12N 2501/998C12N 2501/60C12N 2506/1307C12N 2506/45C12N 2510/00C07K 14/435C12N 5/0696C12N 2501/13
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for producing pancreatic endocrine cells, including introducing (A), (B), (C), or (D) into somatic cells: (A) mutated GLIS1 gene having ≥85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, Pdx1 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof, (B) mutated GLIS1 gene having ≥85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, and Pdx1 gene or gene product(s) thereof. (C) GLIS1 gene or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, Pdx1 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof, and (D) mutated GLIS1 gene having ≥85%-sequence-identity to base sequence of SEQ ID NO: 1 or 2 or gene product(s) thereof, Neurogenin3 gene or gene product(s) thereof, and MafA gene or gene product(s) thereof.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method for producing pancreatic endocrine cells, the method comprising:
 introducing (B) or (D) below into cultured somatic cells to transdifferentiate into a population of pancreatic endocrine cells comprising insulin-producing beta-cells:   (B) a GLIS1 gene or one or more gene products thereof,
 a Neurogenin3 gene or one or more gene products thereof, and 
 a PdX1 gene or one or more gene products thereof; and 
   (D) a GLIS1 gene or one or more gene products thereof,
 a Neurogenin3 gene or one or more gene products thereof, and 
 a MafA gene or one or more gene products thereof, 
   wherein the GLIS1 gene comprises the nucleotide sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and   wherein the population of pancreatic endocrine cells are produced without undergoing an induced pluripotent stem (iPS) cell stage.   
     
     
         16 . The method for producing pancreatic endocrine cells according to  claim 15 , wherein the somatic cells are fibroblasts or mesenchymal stem cells.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.